Dr. Robert Langer Joins the A-Team

At Allevi, we believe that the democratization of bioprinting can help millions lead longer and healthier lives. By empowering scientists to make complex, relevant, personalized 3D tissues so many breakthroughs will be achieved within healthcare and humanity. And we are at the heart of catalyzing this change.

We have already seen so much success from our users bringing to life new ideas. They have shown us how patterning cells and biomaterials in new ways can generate scientific results unseen before. For example, Dr. Binatta Joddar from the University of El Paso Texas published how the difference between lattice and rectangular sheet structures matter for cardiac tissue engineering. On that same note, Dr. Parr and Dr. McAlpine from The University of Minnesota published how the specific placement of iPS neuron cells in relation to supporting cells matters to achieve relevant spinal cord tissue engineering. And these are just a few examples out of the multitude of papers being created by Allevi products.

As Allevi’s publication list grows, we are excited to begin to understand how we can translate these relevant scientific results into impactful products for the benefit of patients. However, we understand that to help millions in the future we have to continually learn from those who have helped millions in the past.

Therefore, we are excited to announce Dr. Robert Langer has joined our Scientific Advisory Board to teach us the fundamentals of how he has translated so many breakthroughs to patients and created new industries. Dr. Langer a Professor at MIT, has helped start several biotechnology companies, has licensed or sub-licensed over 350 patents to different companies and runs one of the largest bioengineering research labs in the world. “I’m delighted to be working with Allevi and their excellent team,” stated Dr. Langer.

We will work closely with Dr. Robert Langer as well as our other amazing advisors, Dr. Anthony Atala, Dr. Yu Shrike Zhang, and Dr. Aleksander Skardal to understand the best way to translate breakthroughs in our bioprinting community to begin to directly help patients at the bedside.